Payment overview · 2025
General Payments
$237.12
12 reported records · 7 companies
Healthcare provider profile · identity verified
Robert Glenn, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HICKORY, NC · NPI 1265411938
Verified facts
What the public records show
CMS Open Payments records show Robert Glenn, M.D. received $237.12 in general payments during 2025 across 12 reported records.
PFIZER INC. accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.83 | 20.2% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.93 | 19.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $39.32 | 16.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.79 | 15.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.03 | 9.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.14 | 9.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.08 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $237.12 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.83 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $47.83 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $46.93 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $36.79 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $24.03 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.03 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.14 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.08 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 89 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
152 | 35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
218 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
19 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 986 | 262 |
| Amlodipine Besylate | Amlodipine Besylate | 509 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 509 | 134 |
| Pantoprazole Sodium | Pantoprazole Sodium | 418 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 359 | 98 |
| Lisinopril | Lisinopril | 354 | 98 |
| Alprazolam | Alprazolam | 336 | 52 |
| Metformin Hcl Er | Metformin Hcl | 325 | 107 |
| Omeprazole | Omeprazole | 304 | 80 |
| Losartan Potassium | Losartan Potassium | 287 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 279 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 224 | 36 |
| Eliquis | Apixaban | 218 | 44 |
| Gabapentin | Gabapentin | 218 | 57 |
| Telmisartan | Telmisartan | 218 | 58 |
| Furosemide | Furosemide | 211 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 210 | 50 |
| Ezetimibe | Ezetimibe | 198 | 57 |
| Potassium Chloride | Potassium Chloride | 187 | 50 |
| Sertraline Hcl | Sertraline Hcl | 174 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 46 |
| Irbesartan | Irbesartan | 169 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 42 |
| Synthroid | Levothyroxine Sodium | 152 | 35 |
| Mounjaro | Tirzepatide | 149 | 20 |
| Tramadol Hcl | Tramadol Hcl | 148 | 27 |
| Cefuroxime | Cefuroxime Axetil | 144 | 109 |
| Bupropion Xl | Bupropion Hcl | 141 | 35 |
| Ozempic | Semaglutide | 136 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 27 |
| Buspirone Hcl | Buspirone Hcl | 130 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 42 |
| Montelukast Sodium | Montelukast Sodium | 119 | 30 |
| Glimepiride | Glimepiride | 117 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 112 | 50 |
| Famotidine | Famotidine | 108 | 31 |
| Allopurinol | Allopurinol | 105 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 104 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 97 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 95 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 95 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 95 | 23 |
| Jardiance | Empagliflozin | 89 | 18 |
| Metformin Hcl | Metformin Hcl | 87 | 25 |
| Lorazepam | Lorazepam | 86 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 85 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 21 |
| Meloxicam | Meloxicam | 79 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 22 |
| Celecoxib | Celecoxib | 74 | 24 |
| Fluconazole | Fluconazole | 74 | 31 |
| Clonazepam | Clonazepam | 72 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 72 | suppressed |
| Carvedilol | Carvedilol | 71 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 71 | 57 |
| Atenolol | Atenolol | 69 | 21 |
| Baclofen | Baclofen | 67 | 15 |
| Chlorthalidone | Chlorthalidone | 67 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 67 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 65 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 45 |
| Azithromycin | Azithromycin | 58 | 49 |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 17 |
| Prednisone | Prednisone | 55 | 39 |
| Trazodone Hcl | Trazodone Hcl | 54 | 15 |
| Finasteride | Finasteride | 53 | 15 |
| Farxiga | Dapagliflozin Propanediol | 49 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 13 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 46 | 19 |
| Fenofibrate | Fenofibrate | 45 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 42 | 11 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Linzess | Linaclotide | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Simvastatin | Simvastatin | 39 | 13 |
| Diazepam | Diazepam | 38 | 11 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | 12 |
| Doxepin Hcl | Doxepin Hcl | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 35 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 34 | 22 |
| Promethazine Hcl | Promethazine Hcl | 34 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 26 |
| Mupirocin | Mupirocin | 32 | 19 |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Colchicine | Colchicine | 31 | 12 |
| Ketoconazole | Ketoconazole | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 18 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Testosterone | Testosterone | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Cephalexin | Cephalexin | 22 | 18 |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Nystatin | Nystatin | 21 | 14 |
| Valsartan | Valsartan | 21 | suppressed |
| Epinephrine | Epinephrine | 20 | 12 |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $237.12 · 12 records | PFIZER INC. | AREXVY, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, JARDIANCE, LINZESS, NURTEC ODT, TRELEGY ELLIPTA, VIBERZI, VOQUEZNA, VRAYLAR, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error